Research publications

Alfred Health research outcomes are published in a wide range of peer reviewed journals. 

Search or browse research publications by year, research area, publication type or keyword.

Clear filter
Publication Details
Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials

McCleary NJ, Harmsen WS, Haakenstad E, Cleary JM, Meyerhardt JA, Zalcberg J, Adams R, Grothey A, Sobrero AF, Van Cutsem E, Goldberg RM, Peeters M, Tabernero J, Seymour M, Saltz LB, Giantonio BJ, Arnold D, Rothenberg ML, Koopman M, Schmoll HJ, Pitot HC, Hoff PM, Tebbutt N, Masi G, Souglakos J, Bokemeyer C, Heinemann V, Yoshino T, Chibaudel B, deGramont A, Shi Q, Lichtman SM

(2022), JNCI Cancer Spectrum, 6(2), pkac014

DOI: 10.1093/jncics/pkac014

Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial

Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, de la Cruz Merino L, Khattak MA, Schadendorf D, Long GV, Ascierto PA, Mandala M, De Galitiis F, Haydon A, Dummer R, Grob JJ, Robert C, Carlino MS, Mohr P, Poklepovic A, Sondak VK, Scolyer RA, Kirkwood JM, Chen K, Diede SJ, Ahsan S, Ibrahim N, Eggermont AMM; KEYNOTE-716 Investigators

(2022), Lancet, 399(10336), 1718-29

DOI: 10.1016/S0140-6736(22)00562-1

Aspirin and the Risk of Colorectal Cancer According to Genetic Susceptibility among Older Individuals

Bakshi A, Cao Y, Orchard SG, Carr PR, Joshi AD, Manning AK, Buchanan DD, Umar A, Winship IM, Gibbs P, Zalcberg JR, Macrae F, McNeil JJ, Lacaze P, Chan AT

(2022), Cancer Prev Res, 15(7), 447-54

DOI: 10.1158/1940-6207.CAPR-22-0011

Development of melanoma clinical quality indicators for the Australian melanoma clinical outcomes registry (MelCOR): A modified Delphi study

Jobson D, Roffey B, Arnold C, Azzi A, Button-Sloan A, Dawson T, Fernandez-Penas P, Fishburn P, Gyorki DE, Hiscutt EL, Jakrot V, Lilleyman A, Lochhead A, Long GV, Mailer S, Mann G, McCormack CJ, Muir J, Pratt GF, Scolyer RA, Shackelton M, Shumack S, Soyer HP, Tan CG, Webb A, Zalcberg J, Morton R, Mar V

(2022), Australas J Dermatol, 63(3), 344-51

DOI: 10.1111/ajd.13848

Removal of BFL-1 sensitises some melanoma cells to killing by BH3 mimetic drugs

Gangoda L, Schenk RL, Tai L, Szeto P, Cheung JG, Strasser A, Lessene G, Shackleton M, Herold MJ

(2022), Cell Death Dis, 13(4), 301

DOI: 10.1038/s41419-022-04776-y

Dramatic clinical response in the treatment of small cell glioblastoma multiforme

Zaman FY, McLean C, Ameratunga M

(2022), J Clin Pharm Ther, 47(6), 832-4

DOI: 10.1111/jcpt.13608

Yield of baseline imaging for distant metastases in high-risk primary melanoma

Yan MK, Adler NR, Pan Y, Chamberlain A, Kelly J, Yap K, Voskoboynik M, Haydon A, Shackleton M, Mar VJ

(2022), J Surg Oncol, 125(8), 1312-7

DOI: 10.1002/jso.26846

Functional Decline in the Cancer Patient: A Review

Muhandiramge J, Orchard SG, Warner ET, van Londen GJ, Zalcberg JR

(2022), Cancers, 14(6), 1398

DOI: 10.3390/cancers14061368

Cardiovascular disease and malignant melanoma

Wang CY, Zoungas S, Voskoboynik M, Mar V

(2022), Melanoma Res, 32(3), 135-141

DOI: 10.1097/CMR.0000000000000817

The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours

Foo T, Goldstein D, Segelov E, Shapiro J, Pavlakis N, Desai J, Yip D, Zalcberg J, Price TJ, Nagrial A, Chantrill L, Burge M, Karapetis CS, Tebbutt N, Roy AC

(2022), Target Oncol, 17(2), 95-110

DOI: 10.1007/s11523-022-00869-y

Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years

Papamichael D, Lopes GS, Olswold CL, Douillard JY, Adams RA, Maughan TS, Van Cutsem E, Venook AP, Lenz HJ, Heinemann V, Kaplan R, Bokemeyer C, Chibaudel B, Grothey A, Yoshino T, Zalcberg J, De Gramont A, Shi Q

(2022), Eur J Cancer, 163, 1-15

DOI: 10.1016/j.ejca.2021.12.007

Recruitment, outcomes, and toxicity trends in phase I oncology trials: Six-year experience in a large institution

Menon S, Davies A, Frentzas S, Hawkins CA, Segelov E, Day D, Markman B

(2022), Cancer Reports, 5(2), e1465

DOI: 10.1002/cnr2.1465

Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma

Kennedy OJ, Kicinski M, Valpione S, Gandini S, Suciu S, Blank CU, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Robert C, Eggermont AMM, Lorigan P, Mandala M

(2022), Eur J Cancer, 165, 97-112

DOI: 10.1016/j.ejca.2022.01.017

18 F-FDG PET/CT features of immune-related adverse events and pitfalls following immunotherapy

Cherk MH, Nadebaum DP, Barber TW, Beech P, Haydon A, Yap KS

(2022), J MED IMAG RADIAT ON, 66(4), 483-94

DOI: 10.1111/1754-9485.13390

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer

Niu J, Maurice-Dror C, Lee DH, Kim DW, Nagrial A, Voskoboynik M, Chung HC, Mileham K, Vaishampayan U, Rasco D, Golan T, Bauer TM, Jimeno A, Chung V, Chartash E, Lala M, Chen Q, Healy JA, Ahn MJ

(2022), Ann Oncol, 33(2), 169-80

DOI: 10.1016/j.annonc.2021.11.002

Defining research and infrastructure priorities for cancer survivorship in Australia: a modified Delphi study

Crawford-Williams F, Koczwara B, Chan RJ, Vardy J, Lisy K, Morris J, Iddawela M, Mackay G, Jefford M

(2022), Support Care Cancer, 30(5), 3805-15

DOI: 10.1007/s00520-021-06744-2

Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors

Rottey S, Clarke J, Aung K, Machiels JP, Markman B, Heinhuis KM, Millward M, Lolkema M, Patel SP, de Souza P, Duca M, Curigliano G, Santoro A, Koyama T, Brown M, Vezina H, He C, Chu QS

(2022), Clin Cancer Res, 28(1), 95-105

DOI: 10.1158/1078-0432.CCR-21-1181

Implementing Optimal Care Pathways for Aboriginal and Torres Strait Islander People With Cancer: A Survey of Rural Health Professionals' Self-Rated Learning Needs

Ristevski E, Ludwick T, Leach M, Thompson S, Iddawela M, Pryce M, Wood E, Davidson K, Gell J

(2022), Int J Integr Care, 22(1), 27

DOI: 10.5334/ijic.6028

Impacts of lung cancer multidisciplinary meeting presentation: Drivers and outcomes from a population registry retrospective cohort study

Lin T, Pham J, Paul E, Conron M, Wright G, Ball D, Mitchell P, Atkin N, Brand M, Zalcberg J, Stirling RG

(2022), Lung Cancer, 163, 69-76

DOI: 10.1016/j.lungcan.2021.12.006

Recruitment, outcomes, and toxicity trends in phase I oncology trials: Six-year experience in a large institution

Menon S, Davies A, Frentzas S, Hawkins CA, Segelov E, Day D, Markman B

(2021), Cancer Reports, 5(2), e1465

DOI: 10.1002/cnr2.1465

1 2 3 4 5